22:23 , Apr 1, 2019 |  BC Extra  |  Clinical News

Roche's ipatasertib-Tecentriq combo leads to 73% ORR in TNBC patients

Roche plans to start a Phase III trial this year to evaluate a combination of ipatasertib plus PD-L1 inhibitor Tecentriq atezolizumab and paclitaxel as first-line treatment of metastatic triple-negative breast cancer following a Phase Ib...
07:00 , May 23, 2016 |  BC Week In Review  |  Clinical News

Ipatasertib: Phase II data

A double-blind, placebo-controlled, international Phase II trial in 253 patients with metastatic CRPC previously treated with docetaxel showed that once-daily 400 mg oral ipatasertib plus Zytiga abiraterone and prednisone non-significantly improved median radiographic PFS (8.2...
08:00 , Feb 5, 2015 |  BC Innovations  |  Product R&D

Addex's allosterics

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging...
07:00 , Mar 31, 2014 |  BioCentury  |  Emerging Company Profile

Indi Molecular: Building better binders

Indi Molecular Inc. 's protein-catalyzed capture platform produces synthetic peptides that could be used as in vivo imaging agents and in vitro diagnostics when low target immunogenicity or suboptimal pharmacokinetics limit the utility of mAbs....
08:00 , Nov 4, 2013 |  BC Week In Review  |  Clinical News

Ipatasertib: Phase II started

Roche disclosed in its 3Q13 earnings that its Genentech unit began the double-blind, placebo-controlled Phase II JAGUAR trial to evaluate oral ipatasertib once daily for the first week of each 2-week cycle plus IV modified...
07:00 , Sep 24, 2012 |  BioCentury  |  Emerging Company Profile

Synbody: Tackling tough targets

Synbody Biotechnology Inc. is using synthetic peptides to create flexible, modular ligands that have high affinity and specificity for their targets. The biotech says its ligands - dubbed synbodies - are easy to manufacture and...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Clinical News

GDC-0068: Phase Ib started

Roche disclosed in its 2Q12 earnings that it began an open-label, dose-escalation, U.S. Phase Ib trial to evaluate GDC-0973 in combination with GDC-0068 in 108 patients with locally advanced or metastatic solid tumors. Roche's Genentech...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Clinical News

GDC-0973: Phase Ib started

Roche disclosed in its 2Q12 earnings that it began an open-label, dose-escalation, U.S. Phase Ib trial to evaluate GDC-0973 in combination with GDC-0068 in 108 patients with locally advanced or metastatic solid tumors. Roche's Genentech...
07:00 , May 28, 2012 |  BC Week In Review  |  Clinical News

GDC-0068: Phase Ib data

An open-label, dose-escalation, international Phase Ib trial in 23 patients with advanced or metastatic solid tumors showed that 100, 200 and 400 mg doses of daily GDC-0068 plus docetaxel and 100 and 200 mg doses...
07:00 , May 21, 2012 |  BC Week In Review  |  Clinical News

GDC-0068: Phase Ib/II started

Roche's Genentech Inc. unit began an international Phase Ib/II trial of GDC-0068 or GDC-0980 ( RG7422 ) in 262 CRPC patients previously treated with docetaxel. The open-label Phase Ib portion will determine the recommended Phase...